The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Mitotane levels predict the outcome of patients with adrenocortical carcinoma treated adjuvantly following radical resection
Open accessAbstract
CONTEXT: Mitotane plasma concentrations ≥ 14 mg/l have been shown to predict tumor response and better survival in patients with advanced adrenocortical carcinoma (ACC). A correlation between mitotane concentrations and patient outcome has not been demonstrated in an adjuvant setting. OBJECTIVE: To compare recurrence-free survival (RFS) in patients who reached and maintained mitotane concentrations ≥ 1 4 mg/l vs patients who did not. DESIGN AND SETTING: Retrospective analysis at six referral European centers. PATIENTS: Patients with ACC who were radically resected between 1995 and 2009 and were treated adjuvantly with mitotane targeting concentrations of 14-20 mg/l. MAIN OUTCOME MEASURES: RFS (primary) and overall survival (secondary). RESULTS: Of the 122 patients included, 63 patients (52%) reached and maintained during a median follow-up of 36 months the target mitotane concentrations (group 1) and 59 patients (48%) did not (group 2). ACC recurrence was observed in 22 patients of group 1 (35%) and 36 patients in group 2 (61%). In multivariable analysis, the maintenance of target mitotane concentrations was associated with a significantly prolonged RFS (hazard ratio (HR) of recurrence: 0.418, 0.22-0.79; P=0.007), while the risk of death was not significantly altered (HR: 0.59, 0.26-1.34; P=0.20). Grades 3-4 toxicity was observed in 11 patients (9%) and was managed with temporary mitotane discontinuation. None of the patients discontinued mitotane definitively for toxicity. CONCLUSIONS: Mitotane concentrations ≥ 14 mg/l predict response to adjuvant treatment being associated with a prolonged RFS. A monitored adjuvant mitotane treatment may benefit patients after radical removal of ACC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The most important prognostic factor is the mitotane plasma level (295).”
From Adrenocortical carcinoma (2014) · cites this paper as [295]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comparative histologic study of 43 metastasizing and nonmetastasizing adrenocortical tumors
Weiss, L. M. (1984) · The American Journal of Surgical Pathology · doi:10.1097/00000478-198403000-00001 · Cited by 920 · cited 2×
“All diagnoses were confirmed by experienced pathologists according to the Weiss criteria with a score of 3, or more, identifying malignancy (18, 19).”
BackgroundMethodCombination Chemotherapy in Advanced Adrenocortical Carcinoma
Faßnacht, M., Terzolo, M., Allolio, B., Baudin, É., Haak, H. R., Berruti, A., Welin, S., Schade‐Brittinger, C., Lacroix, A., Jarząb, B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200966 · Cited by 874
Self-citationPathologic features of prognostic significance in adrenocortical carcinoma
Weiss, L. M., Medeiros, L. J., & Vickery, A. L. (1989) · The American Journal of Surgical Pathology · doi:10.1097/00000478-198903000-00004 · Cited by 818 · cited 2×
“All diagnoses were confirmed by experienced pathologists according to the Weiss criteria with a score of 3, or more, identifying malignancy (18, 19).”
BackgroundMethodBurstein, H. J., Prestrud, A. A., Seidenfeld, J., Anderson, H., Buchholz, T. A., Davidson, N. E., Gelmon, K. A., Giordano, S. H., Hudis, C. A., Malin, J. L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.3756 · Cited by 799
Adrenocortical Carcinoma: Clinical Update
Allolio, B., & Fassnacht, M. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2639 · Cited by 775
Self-citationAdjuvant Mitotane Treatment for Adrenocortical Carcinoma
Terzolo, M., Angeli, A., Faßnacht, M., Daffara, F., Tauchmanovà, L., Conton, P. A., Rossetto, R., Buci, L., Sperone, P., Grossrubatscher, E. M., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa063360 · Cited by 759
Self-citationSargent, D. J., Wieand, H. S., Haller, D. G., Gray, R., Benedetti, J. K., Buyse, M., Labianca, R., Seitz, J. F., O'Callaghan, C. J., Francini, G., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.6071 · Cited by 713 · cited 1×
“RFS is increasingly considered as a valid surrogate endpoint for OS in adjuvant trials being closely related to the efficacy of adjuvant treatment, whereas OS is usually also affected by the treatment adopted upon progression (26, 27).”
BackgroundFassnacht, M., Johanssen, S., Quinkler, M., Bucsky, P., Willenberg, H. S., Beuschlein, F., Terzolo, M., Mueller, H., Hahner, S., Allolio, B., et al. (2009) · Cancer · doi:10.1002/cncr.24030 · Cited by 695
Self-citationIcard, P., Goudet, P., Charpenay, C., Andreassian, B., Carnaille, B., Chapuis, Y., Cougard, P., Henry, J., & Proye, C. (2001) · World Journal of Surgery · doi:10.1007/s00268-001-0047-y · Cited by 543
Adrenocortical carcinoma in the United States: Treatment utilization and prognostic factors
Bilimoria, K. Y., Shen, W. T., Elaraj, D., Bentrem, D. J., Winchester, D. J., Kebebew, E., & Sturgeon, C. (2008) · Cancer · doi:10.1002/cncr.23886 · Cited by 493
Research works printed but not linked: 2
- 1959, Transactions of the Association of American Physicians, 72, 341
- 2009, Journal of Clinical Oncology, 20, 4619
Cited by
Sorted by citations
Items 101–134 of 134
Jebabli, N., Gaïes, E., Eljebari, H., Charfi, R., Lakhal, M., Klouz, A., Salouage, I., & Trabelsi, S. (2015) · Therapies · doi:10.2515/therapie/2015043 · Cited by 3
A current perspective on treatment of adrenocortical carcinoma
Terzolo, M., Francia, S. D., Ardito, A., Perotti, P., Ferrari, L., & Berruti, A. (2014) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2014.931222 · Cited by 3
Self-citationRecent Development of CXCR4-Targeted Nuclear Medicine Research in Adrenocortical Tumors
Wang, M., Chen, Q., Yao, S., & Yu, H. (2025) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/0113895575408753250904112417 · Cited by 2
Liu, X., Shang, J., Fu, Q., Lü, L., Deng, J., Tang, Y., Li, J., Mei, D., Zhang, B., & Zhang, S. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.919027 · Cited by 2
Contrast CT radiomic features add value to prediction of prognosis in adrenal cortical carcinoma
Liu, J., Lin, W., Yan, L., Xie, J., Dai, J., Xu, D., & Zhao, J. (2023) · Endocrine · doi:10.1007/s12020-023-03568-4 · Cited by 2
The Challenge of Managing Adrenocortical Carcinoma: Two Case Studies
Kanjanapan, Y., Prasanna, T., Perampalam, S., & Yip, D. (2015) · International Journal of Endocrine Oncology · doi:10.2217/ije.15.12 · Cited by 2
Peritoneal Metastasis of Retroperitoneal Tumors
Brandl, A., Schäfer, C. B., & Rau, B. (2017) · Springer eBooks · doi:10.1007/978-3-319-51523-6_6 · Cited by 2
Creemers, S. G., Hofland, L. J., & Feelders, R. A. (2016) · Springer eBooks · doi:10.1007/978-3-319-44136-8_12 · Cited by 2
Self-citationZhulikov, Y. А., Kovalenko, E. I., Bokhian, V., & Артамонова, Е. В. (2022) · Malignant tumours · doi:10.18027/2224-5057-2021-11-3-36-44 · Cited by 1
Diagnosis and Management of Adrenocortical Carcinoma
Balderrama-Brondani, V., & Habra, M. A. (2026) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2026.01.006 · Cited by 1
Flauto, F., Neola, G., Vitale, F., & Damiano, V. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105346 · Cited by 1
Carcinoma adrenocortical: presentación y desenlaces en una institución oncológica
Maya, L. F. F., Clavijo, A. ́. G., Madero, A. I., Cuellar, A. A. C., & Carreño-Dueñas, J. A. (2021) · Revista Colombiana de Cancerología · doi:10.35509/01239015.108 · Cited by 1
Krüger, A. F., Schmitz, W., Lamer, S., Triebig, A. S., Maier, T., Fuß, C. T., Angeli, J. P. F., Schlösser, A., Stigloher, C., Faßnacht, M., et al. (2025) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaf198 · Cited by 1
Thérapies ciblées en oncologie endocrinienne : facteurs pronostiques et prédictifs de réponse
Hescot, S., Baudin, É., Borson‐Chazot, F., & Lombès, M. (2013) · Annales d Endocrinologie · doi:10.1016/s0003-4266(13)70017-9 · Cited by 1
Tokura, Y., Kobayashi, M., & Kamai, T. (2020) · IJU Case Reports · doi:10.1002/iju5.12196 · Cited by 1
Tõke, J., Jakab, Z., Stark, J., Huszty, G., Reismann, P., & Tóth, M. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.680853 · Cited by 1
Kerkhofs, T. M. A. (2015) · doi:10.26481/dis.20151112tk · Cited by 1
Freire, D. S. (2014) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2014.tde-24062014-160845
Diagnosi e terapia del carcinoma corticosurrenalico
Terzolo, M., Zaggia, B., Daffara, F., Ardito, A., Basile, V., Ferrari, L., & Berruti, A. (2014) · L Endocrinologo · doi:10.1007/s40619-014-0015-z
Self-citationAdrenal Cortical Carcinoma: Mitotane and Beyond
Francia, S. D., Perotti, P., Basile, V., Germano, A., & Terzolo, M. (2017) · Contemporary Endocrinology · doi:10.1007/978-3-319-62470-9_13
Self-citationSteenaard, R. V., Ettaieb, M. H. T., Kerkhofs, T. M. A., & Haak, H. R. (2021) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2021.1921146
Self-citationAnálise dos genes ATRX e ZNRF3 como fatores de prognóstico do carcinoma adrenocortical
Balderrama-Brondani, V. (2021) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2021.tde-28092021-123423
König, S. (2010) · Goltdammer's Archiv für Strafrecht
AL-Mamari, S. A., & Al-Busaidy, S. S. (2015) · Springer eBooks · doi:10.1007/978-3-319-16301-7_27
Adrenocortical Carcinoma: Diagnosis and Therapy
Terzolo, M., Puglisi, S., Perotti, P., Claps, M., Roca, E., & Berruti, A. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.65243-1
Self-citationMalignant Tumors of the Adrenal Gland
Lee, J. E., Habra, M. A., & Campbell, M. T. (2022) · Holland‐Frei Cancer Medicine · doi:10.1002/9781119000822.hfcm082.pub2
Adrenal Cortical Carcinoma: Clinical Perspectives
Ni, H., & Aung, H. (2017) · EMJ Urology · doi:10.33590/emjurol/10312592
Adrenocortical cancer: late diagnosis of the disease on the example of a clinical case. Case report
Starostina, E. A. (2023) · Terapevticheskii arkhiv · doi:10.26442/00403660.2023.12.202430
Joshi, A. D., Dholakia, K., & Bakshi, G. (2024) · Springer eBooks · doi:10.1007/978-981-99-3378-5_48
Yeoh, P., Sturt, J. A., & Czuber‐Dochan, W. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1829424
Hernández-Félix, J. H., Lagana, M., Cosentini, D., Tacchetti, M. C., Berruti, A., & Rivero, J. D. (2026) · Endocrine Connections · doi:10.1530/ec-26-0334
Self-citationBettini, D. L., Rodella, S., Laganà, M., Turla, A., Berruti, A., & Cosentini, D. (2026) · JCEM Case Reports · doi:10.1210/jcemcr/luag262
Self-citation
Metadata
- Authors
- Terzolo, M., Baudin, A. E., Ardito, A., Kroiss, M., Leboulleux, S., Daffara, F., Perotti, P., Feelders, R. A., deVries, J. H., Zaggia, B., De Francia, S., Volante, M., Haak, H. R., Allolio, B., Al Ghuzlan, A., Fassnacht, M., & Berruti, A.
- Affiliations
- Ospedale San Luigi Gonzaga (IT)
- Universitätsklinikum Würzburg (DE)
- Erasmus MC (NL)
- Amsterdam UMC Location University of Amsterdam (NL)
- Máxima Medisch Centrum (NL)
- Corresponding author
- Ardito, A
- ORCID
- Venue
- European Journal of Endocrinology
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-09
- Volume
- 169
- Issue
- 3
- Pages
- 263-270
- ISSN
- 0804-4643 (ISSN-L)
- 1479-683X
- OpenAlex
- W2142931016
- Cited by
- 134
- References
- 31
- Citations by year
- 2026: 5 · 2025: 3 · 2024: 5 · 2023: 6 · 2022: 11 · 2021: 13 · 2020: 13 · 2019: 19 · 2018: 8 · 2017: 11 · 2016: 8 · 2015: 17 · 2014: 11 · 2013: 3
- FWCI
- 12.75
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- other-oa
- Locations
- European Journal of Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- Institutional Research Information System (Università degli Studi di Brescia) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Funders
- Deutsche Krebshilfe
- Regione Piemonte
- Topics
- Health Sciences › Medicine › Surgery › Adrenal and Paraganglionic Tumors
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
- Keywords
- adrenocortical carcinoma, mitotane, plasma drug concentration, adjuvant therapy, recurrence-free survival, overall survival, treatment response prediction, drug toxicity
- MeSH terms
- Adolescent, Adrenal Cortex, Adrenal Cortex Neoplasms, Adult, Aged, Female, Follow-Up Studies, Humans, Male, Middle Aged, Mitotane, Neoplasm Recurrence, Local, Neoplasm Staging, Retrospective Studies, Survival Analysis, Drug Monitoring, Chemotherapy, Adjuvant, Adrenocortical Carcinoma, Antineoplastic Agents, Hormonal, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
